Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2018 May;103(5):770-777.
doi: 10.1002/cpt.1007. Epub 2018 Jan 31.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Matthew P Goetz  1 , Katrin Sangkuhl  2 , Henk-Jan Guchelaar  3 , Matthias Schwab  4   5   6 , Michael Province  7 , Michelle Whirl-Carrillo  2 , W Fraser Symmans  8 , Howard L McLeod  9 , Mark J Ratain  10 , Hitoshi Zembutsu  11 , Andrea Gaedigk  12 , Ron H van Schaik  13   14 , James N Ingle  1 , Kelly E Caudle  15 , Teri E Klein  2
Affiliations
Practice Guideline

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

Matthew P Goetz et al. Clin Pharmacol Ther. 2018 May.

Abstract

Tamoxifen is biotransformed by CYP2D6 to 4-hydroxytamoxifen and 4-hydroxy N-desmethyl tamoxifen (endoxifen), both with greater antiestrogenic potency than the parent drug. Patients with certain CYP2D6 genetic polymorphisms and patients who receive strong CYP2D6 inhibitors exhibit lower endoxifen concentrations and a higher risk of disease recurrence in some studies of tamoxifen adjuvant therapy of early breast cancer. We summarize evidence from the literature and provide therapeutic recommendations for tamoxifen based on CYP2D6 genotype.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

A.G. is a paid consultant of Millennium Health.

Figures

Figure 1
Figure 1
Tamoxifen Pathway, Pharmacokinetics (57). Permission has been given by PharmGKB and Stanford to use figure.
See this image and copyright information in PMC

References

    1. PharmGKB. [Accessed September 16 2016];Gene Reference Materials for CYP2D6. < https://www.pharmgkb.org/page/cyp2d6RefMaterials>.
    1. Crews KR, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014;95:376–82. - PMC - PubMed
    1. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83:234–42. - PubMed
    1. Crews KR, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012;91:321–6. - PMC - PubMed
    1. Hicks JK, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015;98:127–34. - PMC - PubMed

Publication types

MeSH terms

Substances